# Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

> **NCT00606502** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 201 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pralatrexate
- **DRUG:** Erlotinib
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Folic Acid

## Key facts

- **NCT ID:** NCT00606502
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-06-24
- **Final completion:** 2010-06-24
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606502, "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00606502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*